Patents by Inventor Scott A. Savage

Scott A. Savage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESS FOR THE PREPARATION OF N-((1R,2S,5R)-5-(TERT-BUTYLAMINO)-2-((S)-3-(7-TERT-BUTYLPYRAZOLO[1,5-A][1,3,5]TRIAZIN-4-YLAMINO)-2-OXOPYRROLIDIN-1-YL)CYCLOHEXYL)ACETAMIDE
    Publication number: 20220177482
    Abstract: The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.
    Type: Application
    Filed: February 22, 2022
    Publication date: June 9, 2022
    Inventors: Burcu Selin Aytar, Alina Borovika, Collin Chan, Joerg Deerberg, Nathan R. Domagalski, Martin D. Eastgate, Yu Fan, Michael David Bengt Fenster, Robert V. Forest, Francisco Gonzalez-Bobes, Rebecca A. Green, Matthew R. Hickey, Nathaniel David Kopp, Thomas E. La Cruz, Kathleen Lauser, Hong Geun Lee, David K. Leahy, Helen Y. Luo, Thomas M. Razler, Scott A. Savage, Chris Sfouggatakis, Maxime C.D. Soumeillant, Serge Zaretsky, Bin Zheng, Ye Zhu
  • Process for the preparation of N-((1R,2S,5R)-5-(-butylamino)-2-((S)-3-(7--butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrroldin-1-yl)cyclohexyl)acetamide
    Patent number: 11254679
    Abstract: The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: February 22, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Burcu Selin Aytar, Alina Borovika, Collin Chan, Joerg Deerberg, Nathan R. Domagalski, Martin D. Eastgate, Yu Fan, Michael David Bengt Fenster, Robert V. Forest, Francisco Gonzalez-Bobes, Rebecca A. Green, Matthew R. Hickey, Nathaniel David Kopp, Thomas E. La Cruz, Kathleen Lauser, Hong Geun Lee, David K. Leahy, Helen Y. Luo, Thomas M. Razler, Scott A. Savage, Chris Sfouggatakis, Maxime C. D. Soumeillant, Serge Zaretsky, Bin Zheng, Ye Zhu
  • PROCESS FOR THE PREPARATION OF N-((1R,2S,5R)-5-(TERT-BUTYLAMINO)-2-((S)-3-(7-TERT-BUTYLPYRAZOLO[1,5-A][1,3,5]TRIAZIN-4-YLAMINO)-2-OXOPYRROLIDIN-1-YL)CYCLOHEXYL)ACETAMIDE
    Publication number: 20200223852
    Abstract: The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolodin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.
    Type: Application
    Filed: July 19, 2018
    Publication date: July 16, 2020
    Inventors: Burcu Selin Aytar, Alina Borovika, Collin Chan, Joerg Deerberg, Nathan R. Domagalski, Martin D. Eastgate, Yu Fan, Michael David Bengt Fenster, Robert V. Forest, Francisco Gonzalez-Bobes, Rebecca A. Green, Matthew R. Hickey, Nathaniel David Kopp, Thomas E. La Cruz, Kathleen Lauser, Hong Geun Lee, David K. Leahy, Helen Y. Luo, Thomas M. Razler, Scott A. Savage, Chris Sfouggatakis, Maxime C.D. Soumeillant, Serge Zaretsky, Bin Zheng, Ye Zhu
  • Hepatitis C virus inhibitors
    Patent number: 10494400
    Abstract: The present disclosure relates to methods for making asunaprevir, useful treatment of Hepatitis C virus (HCV) infection, and its intermediates.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: December 3, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Scott A. Savage, Nathan R. Domagalski, Brendan Mack, Purushotham Vemishetti, Yuping Qiu, Michael Fenster, Daniel M. Hallow, Glenn Ferreira, Amanda Rogers, Sha Lou, Lindsay Hobson
  • Methods of producing an HIV maturation inhibitor
    Patent number: 10221208
    Abstract: A method for producing HIV maturation inhibitor compound is set forth using betulin as starting material, and utilizing Lossen rearrangement techniques.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: March 5, 2019
    Assignee: VIIV HEALTHCARE UK (NO.4) LIMITED
    Inventors: Adrian Ortiz, Maxime Soumeillant, Scott A. Savage, Neil A. Strotman, Martin D. Eastgate, Matthew W. Haley, Jeanne Ho, Jeffrey A. Nye, Zhongmin Xu, Susanne Kiau, Tamas Benkovics, Yichen Tan
  • Crystal forms of saxagliptin and processes for preparing same
    Patent number: 8802715
    Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: August 12, 2014
    Assignee: AstraZeneca AB
    Inventors: Jack Z. Gougoutas, Mary F. Malley, John D. DiMarco, Xiaotian S. Yin, Chenkou Wei, Jurong Yu, Truc Chi Vu, Gregory Scott Jones, Scott A. Savage
  • Crystal Forms of Saxagliptin and Processes for Preparing Same
    Publication number: 20140121155
    Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
    Type: Application
    Filed: December 27, 2013
    Publication date: May 1, 2014
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jack Z. Gougoutas, Mary F. Malley, John D. DiMarco, Xiaotian S. Yin, Chenkou Wei, Jurong Yu, Truc Chi Vu, Gregory Scott Jones, Scott A. Savage
  • CRYSTAL FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING SAME
    Publication number: 20120283181
    Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
    Type: Application
    Filed: July 11, 2012
    Publication date: November 8, 2012
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jack Z. Gougoutas, Mary F. Malley, John D. DiMarco, Xiaotian S. Yin, Chenkou Wei, Jurong Yu, Truc Chi Vu, Gregory Scott Jones, Scott A. Savage
  • Crystal forms of saxagliptin and processes for preparing same
    Patent number: 8236847
    Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: August 7, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jack Z. Gougoutas, Mary F. Malley, John D. DiMarco, Xiaotian S. Yin, Chenkou Wei, Jurong Yu, Truc Chi Vu, Gregory Scott Jones, Scott A. Savage
  • Crystal Forms of Saxagliptin and Processes for Preparing Same
    Publication number: 20110257085
    Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
    Type: Application
    Filed: April 6, 2011
    Publication date: October 20, 2011
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jack Z. Gougoutas, Mary F. Malley, John D. DiMarco, Xiaotian S. Yin, Chenkou Wei, Jurong Yu, Truc Chi Vu, Gregory Scott Jones, Scott A. Savage
  • Crystal forms of saxagliptin and processes for preparing same
    Patent number: 7943656
    Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: May 17, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jack Z. Gougoutas, Mary F. Malley, John D. DiMarco, Xiaotian S. Yin, Chenkou Wei, Jurong Yu, Truc Chi Vu, Gregory Scott Jones, Scott A. Savage
  • CRYSTAL FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING SAME
    Publication number: 20090054303
    Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
    Type: Application
    Filed: April 18, 2008
    Publication date: February 26, 2009
    Inventors: Jack Z. Gougoutas, Mary F. Malley, John D. DiMarco, Xiaotian S. Yin, Chenkou Wei, Jurong Yu, Truc Chi Vu, Gregory Scott Jones, Scott A. Savage
  • Asymmetric synthesis of amino-pyrrolidinones
    Patent number: 6770763
    Abstract: A novel process for the asymmetric synthesis of an amino-pyrrolidinone of the type shown below from appropriate pyrrolidinones is described. These compounds are useful as intermediates for MMP and TACE inhibitors.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: August 3, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas A. Magnus, Pasquale N. Confalone, Scott A. Savage, Matthew Yates, Robert E. Waltermir, David J. Meloni, Silvio Campagna
  • Asymmetric synthesis of amino-pyrrolidinones and a crystalline, free-base amino-pyrrolidinone
    Publication number: 20040006137
    Abstract: A novel process for the asymmetric synthesis of an amino-pyrrolidinone of the type shown below is described.
    Type: Application
    Filed: March 14, 2003
    Publication date: January 8, 2004
    Inventors: Robert E. Waltermire, Silvio Campagna, Scott A. Savage, Shailendra Bordawekar, Thomas P. Maduskuie, Sridhar Desikan, Stephen R. Anderson
  • Asymmetric synthesis of amino-pyrrolidinones
    Publication number: 20030236401
    Abstract: A novel process for the asymmetric synthesis of an amino-pyrrolidinone of the type shown below from appropriate pyrrolidinones is described.
    Type: Application
    Filed: March 14, 2003
    Publication date: December 25, 2003
    Inventors: Nicholas A. Magnus, Pasquale N. Confalone, Scott A. Savage, Matthew Yates, Robert E. Waltermire, David J. Meloni, Silvio Campagna